Rockville-based, Micromet, Inc. (NASDAQ: MITI), has started the phase 2 trial of its lymphoblastic leukemia drug, blinatumomab (MT103). Blinatumomab utilizes the body’s T cells to kill cancer cells; it is classified as a new group of agents called BiTE® antibodies.
The drug is targeting adult patients with relapsed B-precursor acute lymphoblastic leukemia or (ALL).
"Relapsed/refractory acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades," said Professor Max Topp, Department of Internal Medicine II, University of Wuerzburg and the study’s coordinating investigator for Europe. "To date blinatumomab has demonstrated an unprecedented level of efficacy and adequate safety in a patient population with limited therapeutic options."
The efficacy and safety study will include 65 patients with the disease. Blinatumomab will be given over a six week treatment cycle with Blinatumomab given for 28 days alternating with two weeks off. Micromet will utilize 40 leading cancer centers and hopes to complete trial enrollment by the end of 2012.